E. coli

Using harmless bacteria to fight cancer

Several bacterial species have pledged promise in fighting tumors. However, most of them are pathogens. In order to use them as a weapon against cancer and other diseases in humans, researchers must find a balance between their therapeutic aggressiveness and safety for the patient. To overcome this problem, researchers at the Helmholtz Centre for Infection Research (HZI) have shifted their focus from pathogenic bacteria to those with a proven safety profile, namely probiotic E. coli. First tests in mice indicate that the probiotic bacteria were indeed efficiently targeting the tumors without generating a toxic effect. The research opens the door to a new approach in fighting cancer.

Probiotic E. coli could be used as a therapeutic agent against cancer.
Probiotic E. coli could be used as a therapeutic agent against cancer.
Source: HZI/ Rohde

Cancers are among the leading causes of morbidity and mortality worldwide. Despite improving treatments such as chemotherapy the disease is still advancing. According to statistics of the World Health Organisation from 2012 (WHO) the number of new cases is expected to rise by about 70 percent over the next two decades. Thus, there is an urgent need for new therapeutic approaches. One possibility is to use pathogenic bacteria such as Salmonella. ‘However, there is one big problem when applying them to human patients’, says Dr Dino Kocijancic, scientist in the department of “Molecular Immunology” at the HZI. ‘We have to modify the bacteria in a way that they do not cause harm. The first clinical trials showed that this is possible but hardly without limiting the therapeutic effects’. In this particular case, the attenuation for safety was too extensive so that the therapeutic power was lost.
To solve this problem the scientists tried an opposing strategy by using probiotic bacteria, which are beneficial rather than harmful to the human host. Kocijancic and his colleagues chose E. coli probiotics which are used by millions of people to treat intestinal disorders. Furthermore, those bacterial strains are already well-studied making it easy to give them new properties and functions.

When testing their approach in tumor bearing mice the researchers found that the E. coli probiotics, notably Symbioflor-2, were very efficient in targeting tumors. ‘This indicates that they are holding a great potential in solid tumor therapy even though their therapeutic potency might be slightly lower than that of Salmonella’, says Kocijancic. ‘However, their superior tumor specificity and the fact that they do not need to be weakened will allow us to use them as bio-vehicles delivering therapeutic molecules into tumors’.

The research indicates that a probiotic therapeutic strain more readily tolerated by an immune compromised cancer patient may allow for systemic application and higher dosing compared to the vastly explored attenuated Salmonella. ’We are sure that this will prove correct in further tests. Thus, our new approach will more readily utilize the advantages of bacteria mediated tumor therapy’, says Dr Siegfried Weiss, head of the research group.


Publication:
Therapy of solid tumors using probiotic Symbioflor-2 – restraints and potential. Dino Kocijancic, Sebastian Felgner, Michael Frahm, Ronja-Melinda Komoll, Aida Iljazovic, Vinay Pawar, Manfred Rohde, Ulrike Heise, Kurt Zimmermann, Florian Gunzer, Juliane Hammer, Katja Crull, Sara Leschner, Siegfried Weiss. Oncotarget; 2016 Mar 10. DOI: 10.18632/oncotarget.8027.


Source: Helmholtz Centre for Infection Research (HZI)

25.04.2016

Read all latest stories

Related articles

Photo

Right in the stomach

Helicobacter creates immune system blind spot

While gastritis and gastric ulcer disease used to be put down to stress and dietary factors, it was discovered in the 1980s that the actual culprit is infection with a bacterium, H. pylori. This…

Photo

Oral vaccination against pancreatic tumours

The world’s first gene cancer therapy study of an innovative oral vaccine is underway at the Surgical Clinic of Heidelberg University Hospital.

Photo

Breakthrough against C. diff

New Clostridioides difficile vaccine on the horizon

Researchers at the University of Exeter first identified a gene in the 'hospital bug' Clostridioides difficile responsible for producing a protein that aids in binding the bacteria to the gut of its…

Related products

Atlas Genetics - Atlas Genetics io system

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd
Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Infectious Disease/Hepatitis

Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Siemens Healthineers